Drug Profile
Research programme: inflammatory disease therapeutics - F-star Therapeutics/Merck Serono
Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator f-star; Merck Serono
- Developer F-star Therapeutics; Merck Serono
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
- 04 Nov 2017 No recent reports of development identified for research development in Inflammation in Europe (Parenteral)